AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Drug Development

Research Ramps Up in Alzheimer’s, Parkinson’s, MS and ALS

Research on Alzheimer’s, specifically in neuroscience, continues with the Alzheimer’s Drug Discovery Foundation, Critical Path Institute, Abbvie, AlzeCure Pharma and more.

September 19, 2022

4 min read

Paul Elias

Business

Bristol Myers Squibb and AbbVie to Cut 360 Jobs Across CA

Both Bristol Myers Squibb and AbbVie filed a WARN notice with the California state government stating they intend to lay off up to 360 people.

September 19, 2022

2 min read

Mark Terry

Bio NC

The Top Biopharma Companies Hiring New Grads Across the U.S.

Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.

August 19, 2022

2 min read

Rosemary Scott

SKYRIZI is the new option for psoriatic arthritis.

Business

Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab

I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.

August 17, 2022

2 min read

Vanessa Doctor, RN

Career Advice

How Removing Bias From Job Descriptions is Key to Your Company’s Success

Job descriptions are the candidate’s first impression of a company. And if that introduction includes exclusionary language, they’re less likely to apply even if they are the perfect fit for the job.

August 9, 2022

5 min read

Kaley Lefevre

Gold colored 2022 sitting over American Dollar bills. Selective focus. Horizontal composition with copy space. Money printing and inflation concept.

Business

Do Q2 Results and Increased M&A Indicate a Recovery for Biotech?

A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.

August 8, 2022

3 min read

Alex Keown

Business

AbbVie and Sosei Lead Slate of Early August R&D Deals

AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

August 2, 2022

4 min read

Mark Terry

Job Trends

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

July 26, 2022

20 min read

Courtesy of picture alliance/Getty Images

Drug Development

Sandoz Takes Aim at AbbVie’s Humira with FDA Acceptance of Biosimilar Application

Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.

July 21, 2022

3 min read

Alex Keown

JOBS